Optimization of Ventilation Therapy Prioritization Strategies

among Patients with COVID-19: Lessons Learned from Real-

World Data of nearly 600,000 Hospitalized Patients

- 4 **Running Title:** Optimizing Ventilation Therapy Prioritization for COVID-19 Patients
- 5 Mohsen Abbasi-Kangevari^{1,†}, Ali Ghanbari^{1,†}, Mohammad-Reza Malekpour^{1,†}, Seyyed-Hadi
- 6 Ghamari¹, Sina Azadnajafabad¹, Sahar Saeedi Moghaddam¹, Mohammad Keykhaei², Rosa
- 7 Haghshenas¹, Ali Golestani¹, Mohammad-Mahdi Rashidi¹, Nazila Rezaei¹, Erfan Ghasemi¹, Negar
- 8 Rezaei^{1,3,*}, Hamid Reza Jamshidi⁴, Bagher Larijani³
- 9 ¹Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population
- 10 Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
- ²Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern
- 12 University, Chicago, IL 60611

- ³Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences
- 14 Institute, Tehran University of Medical Sciences, Tehran, Iran
- ⁴Department of Pharmacology, Faculty of Medicine, Shahid Beheshti University of Medical
- 16 Sciences, Tehran, Iran
- [†]These authors share first-authorship
- ^{*}Address correspondence to Negar Rezaei, MD PhD
- 19 Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences
- 20 Institute, Tehran University of Medical Sciences, Tehran, Iran.
- 21 Address: No. 10, Al-e-Ahmad and Chamran Highway intersection, Tehran, Iran.
- 22 Postal code: 1411713136. Tel/Fax: +982188631293
- 23 E-mail: n.rezaei81@yahoo.com

Summary

24

25

27

28

30

31

32

33

34

36

38

40

41

42

44

45

46

47

48

49

Objective

26 To investigate the benefit of ventilation therapy among various patient groups with COVID-19

admitted to hospitals, based on the real-world data of hospitalized adult patients.

Methods

29 Data used in the longitudinal study included 599,340 records of hospitalized patients. All

participants were categorized based on demographics and their date of hospitalization. Two models

were used in this study: firstly, participants were assessed by their probability of receiving

ventilation therapy during hospitalization using mixed-effects logistic regression. Secondly, the

clinical benefit of receiving ventilation therapy among various patient groups was quantified while

considering the probability of receiving ventilation therapy during hospital admission, as estimated

in the first model.

Findings

Among participants, 60,113 (10.0%) received ventilation therapy, 85,158 (14.2%) passed away due

to COVID-19, and 514,182 (85.8%) recovered. Among all groups with sufficient data for analysis,

39 patients aged 40-64 years who had chronic respiratory diseases (CRD) and malignancy benefitted

the most from ventilation therapy; followed by patients aged 65+ years who had malignancy,

cardiovascular diseases, and diabetes; and patients aged 18-39 years who had malignancy. Patients

aged 65+ who had CRD and cardiovascular disease gained the least benefit from ventilation

43 therapy.

Conclusion

This study promotes a new aspect of treating patients for ventilators: it could be suggested that

rather than focusing on the scarcity of ventilators, guidelines focus on decision-making algorithms

to also take the usefulness of the intervention into account, whose beneficial effect is dependent on

the selection of the right time in the right patient.

Kevwords

- 50 COVID-19; Health Care Rationing; Mechanical Ventilators; Medical Ethics; Resource Allocation;
- 51 Triage.

52

56

Funding

- 53 This work was supported by the World Health Organization (WHO) Eastern Mediterranean
- Regional Office (EMRO) (Grant No. 202693061). The funders had no role in study design, data
- collection and analysis, decision to publish, or preparation of the manuscript.

Research in context

What was already known

Research has been ongoing to investigate the main principles for allocating scarce medical resources during pandemics. Medical experts working at the COVID-19 care units interact with patients of different socioeconomic, clinical, paraclinical, and overall health statuses. While physicians should not be faced with situations where they would be obliged to decide which patient to treat due to the risk of human error as well as the double-burden of life-long emotional toll, the pandemic has increased the likelihood of such dilemmas, especially in settings with limited resources. Serious discussions on the ethical considerations of ventilator allocation were also raised during the pandemic. Utility (maximizing benefits) and equity (distributive justice) were two concerns raised in decision making in such dilemma which has also been considered to be "the toughest triage".

What new knowledge the manuscript contributes

This longitudinal study provides new insights on optimizing the strategies for ventilation therapy prioritization among patients with COVID-19, based on the real-world data of nearly 600,000 hospitalized patients with COVID-19. So far, there has been focus on how to prioritize patients with COVID-19 for ventilation therapy. Nevertheless, there has not been much evidence on how much patients of different age groups with various underlying conditions actually benefitted from ventilation therapy based on real-world data. The results of this study could have a significant message: should the prioritization guidelines for ventilators allocation take no notice of the real-world data, patients might be deprived of ventilation therapy, who could benefit the most from it. This would pave the way to capture clearer picture in the possible future pandemics.

Background

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

The coronavirus disease-2019 (COVID-19) pandemic has far officially claimed more than 5.22 million lives worldwide (1). Acute respiratory distress syndrome (ARDS), a common complication of COVID-19 among critically ill patients, requires medical management involving ventilation therapy. Of all patients diagnosed with COVID-19, 17% to 35% would be hospitalized at intensive care units (ICUs) (2,3), and 9% to 19% would require invasive mechanical ventilation (2,4). The availability of ICU beds varies widely between countries, even among the wealthiest countries (5). While COVID-19 continues to place extraordinary demands on healthcare systems, resulting in severe shortages of essential resources and services (6), the scarcity of ventilators could be the most challenging, as there is typically limited time if mechanical ventilation is vital (7). The estimated number of available invasive mechanical ventilators in various countries would not be adequate to serve all clinically eligible patients during the pandemic (8). Research has been ongoing to investigate the main principles for allocating scarce medical resources during pandemics (9–11). Medical experts working at the COVID-19 care units interact with patients of different socioeconomic, clinical, paraclinical, and overall health statuses. While physicians should not be faced with situations where they would be obliged to decide which patient to treat due to the risk of human error as well as the double-burden of life-long emotional toll, the pandemic has increased the likelihood of such dilemmas, especially in settings with limited resources (12). Thus, prioritization recommendations and guidelines are under development in the hope of helping physicians, especially those less experienced, with the real-time decision-making process based on the resources and contexts (6,13). Serious discussions on the ethical considerations of ventilator allocation were also raised during the pandemic. Utility (maximizing benefits) and equity (distributive justice) were two concerns raised in decision making (14,15) in such dilemma which has also been considered to be "the toughest triage" (7). From a utilitarian perspective, saving the most lives or saving the most life-years by allocation of ventilation to those with higher survival could guide rationing (7,14,15).

Nevertheless, there is not much information about ventilation therapy for patients with COVID-19. Drawing from previous World Health Organization (WHO) guidelines, there are recommendations to indicate which patients with hypoxemic respiratory failure should be considered for non-invasive ventilation and prioritize in settings with limited resources (16). It remains challenging yet imperative to prioritize therapy to patients who will benefit the most from it considering availability and risk, considering the increased risk of infection transmission when the patient undergoes endotracheal intubation and non-invasive ventilation (17). Determining which patients with COVID-19 would benefit the most from ventilation therapy could help optimize the current ventilator allocation guidelines. Thus, the objective of this study was to investigate the benefit of ventilation therapy among various patient groups with COVID-19 admitted to hospitals, based on the real-world data of hospitalized adult patients.

Material and methods

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

Ethics This work was supported by the WHO EMRO Office (EMRO) (Grant No. 202693061). The ethics committee of Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, approved this study under the reference number IR.TUMS.EMRI.REC.1400.034. The confidentiality of the data and the results are preserved. Overview Data used included 599,340 records of hospitalized patients with COVID-19 in Iran who were admitted from February 2020 to June 2021. Patients were categorized based on sex, age, city of residence, the hospitals' affiliated university, date of hospitalization, and comorbidities. First, the probability of patients' ventilation therapy during hospitalization was calculated. Then, patients' survival was assessed and the clinical benefit of ventilation therapy among various patient groups was quantified while considering the probability of receiving ventilation therapy during hospital admission, as estimated in the first model. Data source and variables Data of this longitudinal study were retrieved from the Iranian COVID-19 Registry provided by the Ministry of Health and Medical Education, which was gathered from hospitals and included patients with COVID-19 in Iran from the early days of the pandemic. Data used in the current study included 599,340 records of hospitalized patients who were admitted from February 2020 to June 2021. The study variables included the patients' age; sex; underlying conditions, including diabetes mellitus (DM), cardiovascular diseases (CVD), chronic respiratory disease (CRD), malignancy; receiving ventilation therapy; and COVID-19 outcomes, including recovery or death. **Case definitions** DM, CVD, CRD, and malignancy were obtained from patients' self-reported medical history. The diagnosis of COVID-19 was made by physicians based on a positive Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) result for SARS-CoV-2, or clinical suspicion

defined as (1) at least two of the following symptoms lasting for at least 48 hours: fever (axillary temperature ≥37.5°C), chills, sore throat, stuffy nose, myalgia, fatigue, headache, nausea or vomiting, or diarrhea or (2) at least one respiratory sign or symptom (including cough, shortness of breath), new olfactory or taste disorder, or radiographic evidence of COVID-19–like pneumonia.

Data analysis

Variables

All participants were categorized based on sex, age, city of residence, the hospitals' affiliated university, and their date of hospitalization. Age groups were defined as 18-39, 40-64, and more than 65-year-old participants. The affiliated university were assessed due to the possibility of using disparate approaches and guidelines regarding ventilator allocation policies. The date of hospitalization was also included due to the paramount importance of considering the scarcity of vital equipment at the peak of the COVID-19 epidemic surge. The intervals included in the analysis were as follows: February-March 2020, April-May 2020, June-July 2020, August-September 2020, November-December 2020, January-February 2021, March-April 2021, and May-June 2021. In addition to demographic annotations, patients' data were further assessed for comorbidities and underlying/clinical conditions, which included CRD, CVD, DM, and malignancies.

Statistical methods

Two models were used in this study: in the first model, participants were assessed by their probability of receiving ventilation therapy during hospitalization based on demographic and clinical factors using mixed-effects logistic regression. In the second model, the clinical benefit of receiving ventilation therapy among various patient groups was quantified while considering the probability of receiving ventilation therapy during hospital admission, as estimated in the first model.

166 Estimating the probability of ventilation therapy

First, we used a mixed-effects logistic regression model (18) to estimate the probability of receiving ventilation therapy among patients. The response variable was binary, with "one" representing receiving ventilation therapy. The effects of time intervals, age groups and affiliated university were

- 170 considered as random intercept effects. Sex, ICU admission, CRD, malignancy, CVD, and diabetes
- were random intercept effects that varied among different age groups, as presented in the following:

$$\log\left(\frac{\pi}{1-\pi}\right) = intercept + u_{affiliated\ university} + u_{admission\ time} + u_{intercept_l} + u_{sex_l}$$

$$+ u_{ICU\ admission_l} + u_{CRD_l} + u_{malignancy_l} + u_{CVD_l} + u_{diabetes_l} + \epsilon$$

$$\pi = probability\ of\ receiving\ ventilation\ therapy$$

$$l = 1, ..., n_l\ ; indicate\ age\ group$$

$$u_{affiliated\ university} \sim Normal(0, \sigma_{affiliated\ university})$$

$$u_{time} \sim Normal(0, \sigma_{time})$$

$$\left(\begin{array}{c} u_{sex_l} \\ u_{ICU_l} \\ u_{CRD_l} \\ u_{malignancy_l} \\ u_{CVD_l} \\ u_{diabetes_l} \\ u_{intercept_l} \end{array}\right) \sim Multivariate\ Normal(\mathbf{0}, \mathbf{\Sigma})$$

 Σ is a variance – covariance matrix $\epsilon \sim Normal(0, \sigma)$

172 Estimating the probability of recovery

ventilation therapy

To investigate the extent of benefit among patients with various underlying conditions, the uneven chance of receiving ventilation therapy due to the time of admission, hospital equipment, or resource allocation guidelines used needed to be addressed. First, we divided the patients into 48 groups based on their age groups and underlying conditions, including CRD, malignancy, CVD, DM. Then, considering the high sample size and to simplify the modeling process, a logistic generalized linear model was fitted separately for each group. The response variable was binary with "one" representing recovery. Also, the admission province, admission time, patient sex, and ICU admission were the independent variables. The last term of the model was the interaction between a binary variable, with "one" representing receiving ventilation therapy, and a continuous variable indicating the probability of receiving ventilation therapy obtained from the first model. This interaction gives away two main effects and one interaction coefficient, as presented in the following:

outcome~1 +icu + affiliated university + time + sex + ventilation therapy* probability of receiving

$$\log\left(\frac{\pi}{1-\pi}\right) = intercept + icu + affiliated university + time. period + sex \\ + ventilator. therapy * probability of receiving ventilation therapy + \epsilon \\ \pi = probability of recovery \\ \epsilon \sim Normal(0,\sigma)$$

Main effects

among various patient groups.

The first main effect indicated the ratio of the odds for recovery among patients who received ventilation therapy to the odds for those who did not, while considering other factors constant. The second main effect indicated the ratio of the odds for recovery for a one-unit increase ("zero" probability represents not receiving ventilation therapy, while "one" represents receiving ventilation therapy) in the probability of receiving ventilation therapy, while considering other factors constant.

Interaction coefficient

The interaction coefficient indicated the difference in the slope of the logit probability of recovery for a one-unit increase in the probability of receiving ventilation therapy between the patients who received ventilation compared to those who did not while considering other factors constant. We considered the positive and significant coefficient values to represent the benefit of receiving ventilation for patients who receive ventilation compared to those who did not. Also, a higher value of this coefficient indicated more benefit. The interaction coefficient could be used as an indicator to quantify the benefit of ventilation reception and possibly be used as a criterion for comparison

Results

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Data of 599,340 participants were analyzed, which encompassed 60,113 (10.0%) cases with ventilation therapy, 85,158 (14.2%) cases who died, and 514,182 (85.8%) cases who recovered. The mean (SD) age was 58.5 (18.3) [range= 18-114, being 58.3 (18.2) among women, and 58.6 (18.4) among men]. Characteristics of participants are presented in Table 1. The COVID-19 outcome based on sex, age-groups and underlying diseases are presented in Figure 1. Among all combinations, analysis of eight groups was not available due to paucity of data (Table 2). Among all groups with sufficient data for analysis, patients aged 40-64 years who had CRD and malignancy benefitted the most from ventilation therapy; followed by patients aged 65+ years who had malignancy, cardiovascular diseases, and diabetes; and patients aged 18-39 years who had malignancy. Patients aged 65+ who had CRD, and cardiovascular disease gained the least benefit from ventilation therapy. Among patients with diabetes, patients aged 65+ years benefited from ventilation therapy, followed by 40-64 years. Among patients with cardiovascular diseases, patients aged 18-39 years benefited the most from ventilation therapy, followed by patients aged 40-64 years and 65+ years. Among patients with diabetes and cardiovascular diseases, patients aged 40-64 years benefited from ventilation therapy, followed by 65+ years. Among patients with no history of CRD, malignancy, cardiovascular disease, or diabetes, patients aged 18-39 years benefited the most from ventilation therapy, followed by patients aged 40-64 years and 65+ years (Figure 2).

Discussion

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

This longitudinal study provides new insights on optimizing the strategies for ventilation therapy prioritization among patients with COVID-19, based on the real-world data of nearly 600,000 hospitalized patients with COVID-19. So far, there has been focus on how to prioritize patients with COVID-19 for ventilation therapy (19). Nevertheless, there has not been much evidence on how much patients of different age groups with various underlying conditions actually benefitted from ventilation therapy based on real-world data. Some studies made endeavours to predict COVID-19 severity (20) or the need for mechanical ventilation (21); however, their approaches have not been investigated in the real-world to determine their outcomes. In this study, patients aged 40-64 years who had CRD and malignancy benefitted the most from ventilation therapy, followed by patients aged 65+ years who had malignancy, CVD, and DM; and patients aged 18-39 years who had malignancy. Considering that these patient groups are considered to be at moderate or high risk of severe COVID-19 and possibly require ventilation therapy (22), it was propitious that ventilation therapy could increase their chance of recovery. Patients with COVID-19 who have DM are more likely to require mechanical ventilation (23). Among patients with DM, older age is associated with worse COVID-19 outcomes (24,25). In this study, patients with DM aged 65+ years benefited from ventilation therapy more than those aged 40-64. It is worth mentioning that all patients aged 40+ who only had DM benefitted from ventilation therapy. Pre-existing CVD is independently associated with COVID-19 adverse outcomes (26). Among patients who only had a CVD in this study, the younger the patients, the more they benefitted from ventilation therapy, unlike what was witnessed for DM. The same age pattern was also seen among patients who had DM and CVD. Some guidelines include age group as an additional consideration (19).Individuals also usually prioritize younger patients in situations of absolute scarcity of life sustaining resources; however, simply excluding patients from prioritization solely based on their age could be ethically unjustified and biased against older adults (27). Although age-based

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

discrimination includes moral conflicts and socio-cultural issues, ageism has become more apparent since the beginning of the COVID-19 pandemic. The media has played a significant role in this sense, while broadcasting discussions on the age limits for intensive care and ventilation allocation, unintentionally implying that an older person's life is worth less than a young person's (28). In this study, among otherwise healthy patients, patients aged 18-39 years benefited the most from ventilation therapy, followed by patients aged 40-64 years, and patients aged 65+ years. While COVID-19 has resulted in severe shortage of ventilators (6) worldwide, countries with limited resources face the most challenges to serve all clinically eligible patients during the pandemic (8). In this sense, factoring the level of benefit each patient would receive from ventilation therapy could help optimizing current guidelines. In a study, the public opinion on priorities towards the fair allocation of ventilators during the COVID-19 pandemic was investigated, where people assigned a high priority score to patients with underlying diseases (29). This could imply that people assumed that ventilation therapy would generally improve the outcome for patients with underlying conditions. Nevertheless, the real-world data suggested that patients' age group and underlying diseases could play a significant role in the outcome of ventilation therapy. This calls for knowledge translation by public health authorities and the media to regularly convey the prognostic factors of COVID-19 based on emerging evidence to justify people's expectations from the healthcare systems In a Delphi study, a panel of experts were asked to prioritise the allocation of ventilators based on various medical or non-medical factors. While the panel considered patients with active-malignancy to have low priority in receiving ventilation therapy, the real-world data made it crystal clear that patients with malignancy could also benefit from ventilation therapy. Moreover, the panel did not reach a consensus regarding underlying diseases (30). The deviation of real-world data from the experts' perspectives highlights the potential bias the physicians could have when making a deathlife decision, which needs to be taken into account by future guidelines on the fair allocation of ventilators.

Some guidelines assess patients based on their clinical condition at admission, which could include assessment of irreversible shock, and mortality risk using the Sequential Organ Failure Assessment (SOFA) score (31). They also recommend continuous evaluation for withdrawing patients whose clinical condition is not improving despite ventilation therapy (7). Nevertheless, few studies have assessed the application of the current triage criteria to actual patients. In the early days of the pandemic, a retrospective cohort study highlighted how divergent even supposedly similar triage approaches could be, suggesting that different triage approaches identified substantially other patients for initial consideration for withholding or early withdrawal of mechanical ventilation (32). We did not find any studies that investigated the role of ventilation therapy in improving the course of COVID-19 in a setting where patients have been triaged based on SOFA scores.

Strengths and limitations

This is the first nationwide study to quantify the benefit of ventilation therapy based on the real-world data around 600,000 hospitalized patients of various age groups with COVID-19 who had DM, CVD, malignancy, or CRD. The strength of this study lies in a large sample and data gathering since the early days of the outbreak in Iran. Findings could empower public health authorities to optimize the ventilation therapy prioritization strategies among patients with COVID-19 admitted to hospitals, especially considering that there are currently no national guidelines for allocation of ventilators at the time of resources scarcity in Iran and the decision to prioritize patients for ventilator allocation is performed based on hospital regulations. We realize the limitations of the study. Due to the lack of a national integrated electronic health records system in Iran, many underlying conditions or baseline data of patients, such as their body mass index or behavioral risk factors, were not properly recorded in the COVID-19 registry. Despite the large study population, data points for some patient groups were insufficient for analysis, which need to be addressed in future studies.

New insights and conclusion

The results of this study could have a significant message: should the prioritization guidelines for ventilators allocation take no notice of the real-world data, patients might be deprived of ventilation therapy, who could benefit the most from it. The comparison of real-world evidence with the general population's attitudes and medical experts showed an unexpected bias against older age groups and underlying conditions. This study promotes a new aspect of treating patients for ventilators as a scarce medical resource, considering whether ventilation therapy would improve the patient's clinical outcome. This gains significance considering the divergent outcomes of existing guidelines, especially for patients meeting the lowest priority criteria for mechanical ventilation (32). As a rapidly evolving crisis, numerous therapeutic or preventive approaches are being investigated to lessen the burden of the COVID-19 pandemic (33,34). It could be suggested that rather than focusing on the scarcity of ventilators, guidelines focus on evidence-based decision-making algorithms to also take the usefulness of the intervention into account, similar to some other medications, whose beneficial effect is dependent on the selection of the right time in the right patient (35).

Acknowledgement

We thank all of our colleagues at the Non-Communicable Diseases Research Center (NCDRC), Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical

Sciences, and the supporting roles in Ministry of Health and Medical Education (MOHME) of Iran

and WHO Eastern Mediterranean Regional Office (EMRO) who made the conduction of this study

possible. The authors would like to appreciate the invaluable contribution of Professor Farshad

Farzadfar to this project. They would also like to express their most sincere gratitude to all frontline

healthcare workers across the globe during this pandemic.

Ethical issues

The ethics committee of Endocrinology and Metabolism Research Center, Endocrinology and

Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran,

324 approved this study under the reference number IR.TUMS.EMRI.REC.1400.034. The confidentiality of the data and the results are preserved. 325 **Competing interests** 326 327 None **Funding** 328 329 This work was supported by the WHO EMRO Office (EMRO) (Grant No. 202693061). The 330 funders had no role in study design, data collection and analysis, decision to publish, or preparation 331 of the manuscript. **Data sharing statement** 332 333 De-identified, individual participant data will be made available upon requests directed to the 334 corresponding author; after the approval of a proposal, data can be shared through a secure online

335

platform.

References

- 337 1. Ritchie H, Ortiz-Ospina E, Beltekian D, Mathieu E, Hasell J, Macdonald B, et al.
- Coronavirus Pandemic (COVID-19). Our World Data [Internet]. 2020 Mar 5 [cited 2021 Aug
- 339 6]; Available from: https://ourworldindata.org/coronavirus
- 340 2. Potere N, Valeriani E, Candeloro M, Tana M, Porreca E, Abbate A, et al. Acute
- 341 complications and mortality in hospitalized patients with coronavirus disease 2019: A
- 342 systematic review and meta-analysis. Vol. 24, Critical Care. BioMed Central; 2020.
- 343 3. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of
- 344 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical
- Characterisation Protocol: Prospective observational cohort study. BMJ. 2020 May;369.
- 346 4. Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The
- prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2;
- 348 COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS
- 349 One. 2020 Jun;15(6 June).
- 350 5. Verdonk F, Zacharowski K, Ahmed A, Orliaguet G, Pottecher J. A multifaceted approach to
- intensive care unit capacity. Lancet Public Heal [Internet]. 2021 Jul 1 [cited 2021 Nov
- 352 17];6(7):e448. Available from:
- 353 http://www.thelancet.com/article/S2468266721001316/fulltext
- 6. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair Allocation of
- Scarce Medical Resources in the Time of Covid-19. N Engl J Med [Internet]. 2020 May 21
- 356 [cited 2020 Sep 3];382(21):2049–55. Available from:
- 357 http://www.nejm.org/doi/10.1056/NEJMsb2005114
- 358 7. Truog RD, Mitchell C, Daley GQ. The toughest triage Allocating ventilators in a
- pandemic [Internet]. Vol. 382, New England Journal of Medicine. Massachussetts Medical
- 360 Society; 2020 [cited 2020 Sep 3]. p. 1973–5. Available from:
- 361 http://www.nejm.org/doi/10.1056/NEJMp2005689
- 362 8. Dos Santos MJ, Martins MS, Santana FLP, Furtado MCSPC, Miname FCBR, Pimentel

- 363 RRDS, et al. COVID-19: Instruments for the allocation of mechanical ventilators- A
- narrative review [Internet]. Vol. 24, Critical Care. BioMed Central Ltd; 2020 [cited 2021 Feb
- 365 26]. p. 582. Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-
- 366 020-03298-3
- 367 9. Adeniji KA, Cusack R. The Simple Triage Scoring System (STSS) successfully predicts
- mortality and critical care resource utilization in H1N1 pandemic flu: A retrospective
- analysis. Crit Care [Internet]. 2011 Jan 26 [cited 2020 Dec 25];15(1). Available from:
- 370 https://pubmed.ncbi.nlm.nih.gov/21269458/
- 371 10. Christian MD, Hawryluck L, Wax RS, Cook T, Lazar NM, Herridge MS, et al. Development
- of a triage protocol for critical care during an influenza pandemic. CMAJ [Internet]. 2006
- 373 Nov 21 [cited 2020 Dec 25];175(11):1377–81. Available from:
- 374 https://pubmed.ncbi.nlm.nih.gov/17116904/
- 375 11. Challen K, Bentley A, Bright J, Walter D. Clinical review: Mass casualty triage Pandemic
- influenza and critical care [Internet]. Vol. 11, Critical Care. Crit Care; 2007 [cited 2020 Dec
- 377 25]. Available from: https://pubmed.ncbi.nlm.nih.gov/17490495/
- 378 12. The Lancet. COVID-19: protecting health-care workers [Internet]. Vol. 395, The Lancet.
- Lancet Publishing Group; 2020 [cited 2020 Sep 4]. p. 922. Available from:
- 380 https://doi.org/10.1016/
- 381 13. Swiss Academy Of Medical Sciences. COVID-19 pandemic: triage for intensive-care
- treatment under resource scarcity. Swiss Med Wkly [Internet]. 2020 Mar 23 [cited 2021 Feb
- 383 25];150:w20229. Available from: https://pubmed.ncbi.nlm.nih.gov/32208495/
- 384 14. Basu S. Approaches to critical care resource allocation and triage during the COVID-19
- pandemic: an examination from a developing world perspective. J Med Ethics Hist Med
- 386 [Internet]. 2021 Feb 28 [cited 2022 Feb 7];14:1–10. Available from:
- 387 https://jmehm.tums.ac.ir/index.php/jmehm/article/view/941
- 388 15. Asghari F, Tehrani SS. Ethical Issues in Responding to the COVID-19 Pandemic; A
- Narrative Review. Front Emerg Med [Internet]. 2020 Apr 28;4(2s SE-Review article).

- 390 Available from: https://fem.tums.ac.ir/index.php/fem/article/view/390
- 391 16. Africa WHORO for. Management of severe / critical cases of COVID-19 with non-invasive
- or mechanical ventilation: based on information as at 1st June 2020 [Internet]. Brazzaville PP
- Brazzaville: World Health Organization. Regional Office for Africa; 2020. (WHO Regional
- Office for Africa COVID-19 Rapid Policy Brief Series; 003-01). Available from:
- 395 https://apps.who.int/iris/handle/10665/332340
- 396 17. Izadi N, Eshrati B, Mehrabi Y, Etemad K, Hashemi-Nazari SS. The national rate of intensive
- care units-acquired infections, one-year retrospective study in Iran. BMC Public Health
- 398 [Internet]. 2021 Dec 1 [cited 2021 Nov 17];21(1):1–8. Available from:
- https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10639-6
- 400 18. Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. Appl
- 401 Longitud Data Anal Epidemiol A Pract Guid [Internet]. 2013 Jan 1 [cited 2021 Nov 20];1-
- 402 321. Available from: https://www.cambridge.org/core/books/applied-longitudinal-data-
- 403 analysis-for-epidemiology/2D3284A1794498DB74039E5E58C11114
- 404 19. White DB, Lo B. A Framework for Rationing Ventilators and Critical Care Beds During the
- 405 COVID-19 Pandemic. JAMA [Internet]. 2020 May 12 [cited 2021 Oct 26];323(18):1773-4.
- 406 Available from: https://jamanetwork.com/journals/jama/fullarticle/2763953
- 407 20. Mahdavi M, Choubdar H, Zabeh E, Rieder M, Safavi-Naeini S, Jobbagy Z, et al. A machine
- learning based exploration of COVID-19 mortality risk. PLoS One [Internet]. 2021 Jul 1
- 409 [cited 2021 Oct 26];16(7):e0252384. Available from:
- 410 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252384
- 411 21. Hiremath A, Bera K, Yuan L, Vaidya P, Alilou M, Furin J, et al. Integrated Clinical and CT
- 412 Based Artificial Intelligence Nomogram for Predicting Severity and Need for Ventilator
- Support in COVID-19 Patients: A Multi-Site Study. IEEE J Biomed Heal Informatics.
- 414 2021;25(11):4110–8.
- 415 22. Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, et al. Severe Outcomes
- 416 Among Patients with Coronavirus Disease 2019 (COVID-19) United States, February 12–

- 417 March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343–6.
- 418 23. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes
- of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care [Internet]. 2020
- 420 Apr 27 [cited 2021 Nov 6];8(1):1343. Available from: /pmc/articles/PMC7222577/
- 421 24. Rezaei N, Montazeri F, Malekpour M-R, Ghanbari A, Azadnajafabad S, Mohammadi E, et
- 422 al. COVID-19 in patients with diabetes: factors associated with worse outcomes. J Diabetes
- 423 Metab Disord 2021 [Internet]. 2021 Oct 28 [cited 2021 Nov 6];1–10. Available from:
- 424 https://link.springer.com/article/10.1007/s40200-021-00910-3
- 425 25. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19
- in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes
- 427 Endocrinol. 2020 Sep 1;8(9):782–92.
- 428 26. Xu J, Xiao W, Liang X, Shi L, Zhang P, Wang Y, et al. A meta-analysis on the risk factors
- adjusted association between cardiovascular disease and COVID-19 severity. BMC Public
- 430 Heal 2021 211 [Internet]. 2021 Aug 11 [cited 2021 Nov 6];21(1):1–49. Available from:
- 431 https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-11051-w
- 432 27. White DB, Katz MH, Luce JM, Lo B. Who should receive life support during a public health
- 433 emergency? Using ethical principles to improve allocation decisions. Ann Intern Med
- 434 [Internet]. 2009 Jan 20 [cited 2021 Apr 23];150(2):132-8. Available from:
- 435 /pmc/articles/PMC2629638/
- 436 28. Silva MF, da Silva DSM, de Macedo Bacurau AG, Francisco PMSB, de Assumpção D, Neri
- 437 AL, et al. Ageismo contra idosos no contexto da pandemia da covid-19: uma revisão
- 438 integrativa. Rev Saude Publica [Internet]. 2021 Apr 14 [cited 2022 Feb 7];55:1–13. Available
- from: http://www.scielo.br/j/rsp/a/YrY9rX7jNPq6LjpsKsYQXNr/?lang=pt
- 440 29. Abbasi-Kangevari M, Arshi S, Hassanian-Moghaddam H, Kolahi A-A. Public Opinion on
- 441 Priorities towards Fair Allocation of Ventilators during COVID-19 Pandemic: A nationwide
- survey. Front Public Heal. 1AD;0:2074.
- 443 30. Ghamari S-H, Abbasi-Kangevari M, Zamani N, Hassanian-Moghaddam H, Kolahi A-A.

- edRxiv preprint doi: https://doi.org/10.1101/2022.08.04.22278438; this version posted August 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

 It is made available under a CC-BY-NC-ND 4.0 International license. medRxiv preprint doi: https://doi.org/10.1101/2022.08.04. 444 Priorities Towards Fair Allocation of Ventilators During COVID-19 Pandemic: A Delphi 445 Study. Front Med. 2022 Jan 24;0:3143. 446 31. Han S, Health VK-DM and P, 2020 undefined. Clinical and ethical considerations in 447 allocation of ventilators in an influenza pandemic or other public health disaster: a 448 comparison of the 2007 and 2015 New York. cambridge.org [Internet]. 2021 [cited 2021 Oct 449 26]; Available from: https://www.cambridge.org/core/journals/disaster-medicine-and-public-450 health-preparedness/article/clinical-and-ethical-considerations-in-allocation-of-ventilators-in-451 an-influenza-pandemic-or-other-public-health-disaster-a-comparison-of-the-2007-and-2015-452 new-york-state-ventilator-allocation-guidelines/277BB3C5CC9EC9567E528516FBD2A5CD 453 32. Wunsch H, Hill AD, Bosch N, Adhikari NKJ, Rubenfeld G, Walkey A, et al. Comparison of 454 2 Triage Scoring Guidelines for Allocation of Mechanical Ventilators. JAMA Netw open 455 2020 Dec 1 [cited 2021 Apr 23];3(12):e2029250. Available from: 456 /pmc/articles/PMC7737087/ 457 33. Malekpour MR, Abbasi-Kangevari M, Azadnajafabad S, Ghamari SH, Rezaei N, Rezazadeh-458 Khadem S, et al. How the scientific community responded to the COVID-19 pandemic: A 459 subject-level time-trend bibliometric analysis. PLoS One [Internet]. 2021 Sep 1 [cited 2021 460 Nov 8];16(9). Available from: https://pubmed.ncbi.nlm.nih.gov/34591941/ 461 34. Khanali J, Malekpour MR, Kolahi AA. Improved dynamics of sharing research findings in 462 the COVID-19 epidemic compared with the SARS and Ebola epidemics. BMC Public Health 463 [Internet]. 2021 Dec 1 [cited 2021 Nov 8];21(1). Available from: 464 https://pubmed.ncbi.nlm.nih.gov/33422049/
- 465 35. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med [Internet]. 2021 Feb 466 25 [cited 2021 Nov 8];384(8):693–704. Available from: 467

https://www.nejm.org/doi/10.1056/NEJMoa2021436

Figure legends

469

- Figure 1. COVID-19 outcome based on (A) sex, (B) cardiovascular disease, (C) chronic respiratory
- disease, (D) malignancy, (E) diabetes mellitus, and (F) age groups.
- Figure 2. Patient groups who significantly benefited from ventilation therapy: estimated benefit
- 473 (95% Confidence Interval)

475 Tables

476

Table 1. Characteristics of participants

	1	1
Variable	N (%)	
Demographics		
Sex		
Female	291,267	7 (48.6)
Male	308,073	3 (51.4)
Age		
18-39 years	113,21	1 (18.9)
40-64 years	240,298	3 (40.1)
More than 65 years	245,83	1 (41.0)
Underlying conditions		
CVD		
Yes	110,593	3 (18.5)
No	488,747	7 (81.5)
DM		
Yes	84,973	(14.2)
No	514,367	7 (85.8)
COPD		
Yes	26,153	(4.4)
No	573,187	7 (95.6)
Malignancy		
Yes	10610 ((2.0)
No	588730	(98.0)
Outcomes		
Ventilation therapy	60,113	(10.0)
Death	85,158	(14.2)
Recovery	514,182	2 (85.8)

Table 2. The estimated benefit of ventilation therapy among patients of different age groups with various underlying conditions

-										
id	COPD	Malignancy	CVD	DM	Age	Benefit*	p-value	Observation	Observation	Observation
								(Total**)	(Ventilation***)	(Recovery****)
1	No	No	No	No	18-39	1.983	< 0.001	103991	8574	100269
2	No	No	No	No	40-64	1.728	< 0.001	171041	14566	155469
3	No	No	No	No	65+	1.369	< 0.001	139453	14014	108579
4	No	No	No	Yes	18-39	1.267	N/S	2827	288	2654
5	No	No	No	Yes	40-64	1.455	< 0.001	22096	2214	19465
6	No	No	No	Yes	65+	1.72	< 0.001	23258	2705	17752
7	No	No	Yes	No	18-39	1.836	0.008	2895	336	2667
8	No	No	Yes	No	40-64	1.31	< 0.001	22712	2539	20251
9	No	No	Yes	No	65+	1.266	< 0.001	43934	5722	34249
10	No	No	Yes	Yes	18-39	-2.412	N/S	401	46	361
11	No	No	Yes	Yes	40-64	1.877	< 0.001	10660	1276	9088
12	No	No	Yes	Yes	65+	1.427	< 0.001	19903	2598	15205
13	No	Yes	No	No	18-39	3.639	< 0.001	1136	136	858
14	No	Yes	No	No	40-64	1.255	0.004	3788	528	2816
15	No	Yes	No	No	65+	0.691	N/S	3085	501	2098
16	No	Yes	No	Yes	18-39	N/A	N/A	16	2	15
17	No	Yes	No	Yes	40-64	-0.324	N/S	313	44	242
18	No	Yes	No	Yes	65+	2.592	N/S	388	72	258
19	No	Yes	Yes	No	18-39	N/A	N/A	21	6	16
20	No	Yes	Yes	No	40-64	-0.808	N/S	234	44	181
21	No	Yes	Yes	No	65+	1.867	N/S	617	111	440
22	No	Yes	Yes	Yes	18-39	N/A	N/A	7	1	6
23	No	Yes	Yes	Yes	40-64	4.885	N/S	132	16	99
24	No	Yes	Yes	Yes	65+	3.79	0.049	279	45	206
25	Yes	No	No	No	18-39	0.499	N/S	1685	238	1582
26	Yes	No	No	No	40-64	0.473	0.041	5958	721	5204
27	Yes	No	No	No	65+	0.466	N/S	7095	1015	5391
28	Yes	No	No	Yes	18-39	241.684	N/S	44	8	40
29	Yes	No	No	Yes	40-64	3.137	0.005	834	123	696
30	Yes	No	No	Yes	65+	0.605	0.003 N/S	1295	172	977
31	Yes	No		No	18-39	445.595	N/S	131	14	118
32	Yes	No	Yes Yes	No	40-64	0.651	N/S	1519	221	1348
	Yes				65+	0.031				3329
33		No	Yes	No			0.032	4488 21	730 3	
34	Yes	No	Yes	Yes	18-39	N/A	N/A			18
35	Yes	No	Yes	Yes	40-64	0.934	N/S	698	105	572
36	Yes	No	Yes	Yes	65+	2.473	<0.001	1711	277	1274
37	Yes	Yes	No	No	18-39	-383.91	N/S	34	6	25
38	Yes	Yes	No	No	40-64	6.504	0.017	183	31	120
39	Yes	Yes	No	No	65+	-0.061	0.982	182	29	120
40	Yes	Yes	No	Yes	40-64	N/A	N/A	14	1	11
41	Yes	Yes	No	Yes	65+	-338.243	1.00	31	4	22
42	Yes	Yes	Yes	No	18-39	N/A	N/A	1	0	1
43	Yes	Yes	Yes	No	40-64	-6.389	1.00	24	5	15
44	Yes	Yes	Yes	No	65+	-3.169	0.494	80	16	49
45	Yes	Yes	Yes	Yes	18-39	N/A	N/A	1	1	1
46	Yes	Yes	Yes	Yes	40-64	N/A	N/A	12	2	9

*The interaction coefficient of the second model

**The total number of patients with COVID-19 who were admitted to the hospital in each group

***The total number of patients with COVID-19 who received ventilation therapy in each group

***The total number of patients with COVID-19 who received after hospital admission in each group



Yes

No





